Annuncio • Apr 10
Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited. Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology.
Getinge and Pennamed has combined 350 employees.
Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026. Annuncio • Mar 12
Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026 Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member. Annuncio • Jan 28
Getinge AB (publ), Annual General Meeting, Apr 21, 2026 Getinge AB (publ), Annual General Meeting, Apr 21, 2026. Annuncio • Jan 27
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60). Annuncio • Dec 19
Getinge AB Announces Malin Persson Declines Re-Election to the Board Getinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026. Annuncio • Oct 21
Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025 Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. Annuncio • Jul 02
Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 Index Getinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index Annuncio • Mar 18
Getinge Introduces Neural Pressure Support for the Servo-U Ventilator System Getinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive. Annuncio • Jan 29
Getinge AB (publ), Annual General Meeting, Apr 22, 2025 Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden Annuncio • Jan 28
Getinge AB (publ) Provides Organic Sales Guidance for the Year 2025 Getinge AB (publ) provided organic sales guidance for the year 2025. The company have a positive outlook on 2025 and expect organic sales growth of 2%-5% for the full year 2025. Annuncio • Nov 28
Getinge AB (Publ) Announces Changes of the Nomination Committee Getinge AB (publ) announced that the composition of Getinge AB (publ)'s Nomination Committee ahead of the 2025 Annual General Meeting has been updated following changed ownership structure in the company. As a consequence, Carnegie Fonder has appointed Simon Blecher as member of the Nomination Committee. This means that Getinge's Nomination Committee ahead of the 2025 Annual General Meeting comprises the company's Chairman, Johan Malmquist, and representatives from the following owners, listed by size: 1. Carl Bennet AB: Carl Bennet 2. Fourth Swedish National Pension Fund: Jannis Kitsakis 3. AMF Pension & Fonder: Dick Bergquist 4. Carnegie Fonder: Simon Blecher 5. Swedbank Robur: Marianne Nilsson. Annuncio • Nov 09
Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024 Getinge appointed Alexandra Holland as the new Executive Vice President of Communications effective November 11, 2024. Alexandra will become a member of the Getinge Executive Team and lead the development, advancement, and execution of the company's communications and public affairs strategy. Alexandra has dedicated her career to healthcare, including almost 15 years at Johnson & Johnson in the consumer, corporate, and medtech sectors. Most recently, Alexandra served as Vice President, Business and Culture Communications, MedTech, responsible for championing key initiatives to improve and protect reputation, drive business results, advance culture, and deliver value to patients, customers and shareholders. Alexandra Holland will report to Mattias Perjos and be a member of Getinge's executive team. She will be based in the United States and will take office on November 11th. Annuncio • Sep 13
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners on September 11, 2024. All conditions for the transaction have now been fulfilled. Annuncio • Aug 23
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million on August 22, 2024. Approximately $477 million, on a cash and debt free basis, for all issued and outstanding shares, of which $253 million is payable in cash on closing. The earn-out payments are expected to be paid between 2024 and 2026 if agreed upon regulatory and financial performance milestones are achieved and may exceed $224 million in aggregate. The initial payout related to the acquisition will be financed through a bridge loan provided by SEB. In 2023, Paragonix Technologies reported revenues of $43.1 million. Upon closing, Paragonix will become a wholly owned subsidiary of Getinge.
The Boards of Directors of both Paragonix and Getinge have approved the transaction. The transaction is subject to subject to antitrust regulations and pending the satisfaction of customary closing conditions. The closing is expected to take place late Q3 or early Q4 2024.
Sheppard, Mullin, Richter & Hampton LLP is acted as legal advisor, Knobbe, Martens, Olson & Bear, LLP is acted as Intellectual Property counsel and UBS Investment Bank is acted as exclusive financial advisor to Paragonix. Annuncio • Jul 01
Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024 Getinge AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Jul 18, 2024 Annuncio • Apr 23
Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024 Getinge AB (publ)'s Annual General Meeting held on 22 April 2024, approved in accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.40 per share. 24 April 2024 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting 29 April 2024. Annuncio • Mar 08
Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3 Getinge announced the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch. Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech. The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable. Annuncio • Jan 23
Getinge Announces CFO Changes Lars Sandström is leaving the position as Getinge's CFO for a new opportunity outside of the company. He will be succeeded by Agneta Palmér, who has been working at Getinge since 2018, most recently in the role of Executive Vice President Operational Services and member of the executive management team. Agneta Palmér most recently served as Executive Vice President Operational Services and prior to that she was Vice President Corporate Control at Getinge. She has previously held similar positions at AB Volvo. The change will take effect at the end of March, when Lars Sandström leaves Getinge. Annuncio • Oct 12
Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million. Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million on October 11, 2023. The acquisition has been financed through cash on hand and existing credit facilities. The statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has passed. The transaction is closed and is not subject to further regulatory approvals or waiting periods.Getinge AB (publ) (OM:GETI B) completed the acquisition of Healthmark Industries Company, Inc. on October 11, 2023. Annuncio • Sep 20
Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023 Getinge announced that Jeanette Hedén Carlsson has decided to resign after 6 years as Executive Vice President, Brand & Communication, and member of the Executive Team. The process to recruit a successor will start immediately. Jeanette Hedén Carlsson will continue in her current role until December 31, 2023. Annuncio • Jul 08
Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite Getinge announced clearance from the US FDA for Servo-air®? Lite, a wall gas independent non-invasive mechanical ventilator. Servo-air®?lite is Getinge's turbine-driven ventilator for non-invasive ventilation. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. It features embedded workflows, support for High Flow therapy, CO2 monitoring option and tools to support escalation of therapy if needed to. The product is expected to be available for customers in the US from September 2023. Annuncio • Jun 01
Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million. Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million on May 31, 2023. The consideration comprises of approximately $120 million in cash on closing, on a cash and debt free basis. In addition, a maximum earn out of approximately $170 million can be paid out in 2024 - 2026 if agreed net revenue performance milestones are achieved in 2023 - 2025. The acquisition will be financed through cash at hand and Getinge's net debt to EBITDA ratio is expected to be impacted by 0.3x at the closing of deal. Getinge expects to have fully integrated HPNE by the end of 2024 and anticipates no material integration costs in 2023 - 2024. The acquisition is not expected to have a material impact on Getinge's operating profit and earnings per share in 2023.
The transaction is subject to and conditional upon customary consents, closing and regulatory conditions being fulfilled, including review by the Committee on Foreign Investment in the United States and completion of the statutorily required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in Q3 2023. Annuncio • Feb 03
Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023 Getinge provided financial guidance for the first half, second half and full year of 2023. For 2023 the company expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science.Whereas the second half of the year is expected to be stronger. This will result in healthy growth for the company in the second half of the year.Anticipated organic sales growth of 2-5% for the full-year. Annuncio • Feb 02
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) proposed dividend per share of SEK 4.25 (SEK 4.00). Annuncio • Jan 30
Getinge AB to Report Q4, 2022 Results on Feb 01, 2023 Getinge AB announced that they will report Q4, 2022 results on Feb 01, 2023 Annuncio • Feb 05
Getinge AB Proposes Executive Changes Getinge’s Nomination Committee proposes that Kristian Samuelsson, Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital, is elected new member of the Board at the Annual General Meeting on April 20, 2021. Kristian Samuelsson is proposed to succeed Johan Stern, who has declined re-election. Annuncio • Nov 11
Getinge Is Announcing A Recall of HLS Set Advanced Products Getinge is announcing a global medical device recall for the HLS Set Advanced products due to a potential breach in sterile packaging. To date, there are no known adverse events associated with illness or injuries related to the mentioned products. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. The HLS Set Advanced is used for extracorporeal respiratory and/or cardiovascular support. Getinge has identified that a limited number of HLS Set Advanced products delivered worldwide beginning October 2018 could have a damaged sterile packaging. The affected products have a shelf life of 2 years and Getinge cannot estimate how many products remain with impacted customers. The cost for the recall is not material. All affected customers will or have received communication from Getinge regarding this recall according to local requirements. Annuncio • Oct 18
Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021 Getinge AB provided no guidance for the fourth quarter of 2020 and for year 2021, because it all hinges on the -- both, of course, the -- say, how company handle the second wave of COVID-19, but also then the comeback of elective surgeries. Annuncio • Oct 16
Getinge Not to Present Outlook for the Full Year 2020 Due to the continuing uncertainty caused by the COVID-19 pandemic, Getinge has decided not to present outlook for the expected increase in the net sales for the full year 2020. Annuncio • Oct 04
Getinge Announces Ventilation Technology for Both Premature Babies and Adults Getinge that is groundbreaking both for premature babies and adults. Born 12 weeks too early with a 50/50 chance at survival, Sabina Checketts has grown up to becoma neonatal doctor herself, usising new therapies and sophisticated technology to improve outcomes for premature babies. One such technique called NAVA, invented by Getinge, utilizes sensors to help babies on ventilators breathe more easily and naturallyand it's increasingly being used on adults. And a new randomized study shows that NAVA can significantly shorten the time on the ventilator. Thirty-three years after her early birth, Checketts now works as a neonatal doctor in London. The ventilator that helped Checketts survive was a far cry from what she sees now when she treats premature babies. As vulnerable premature babies fight to stay alive one of the most critical issues is something most people never think twice about - breathing. A pivotal advance in neonatal medicine - and one that has a major impact in adult critical care - has been the development of better ventilators. One ventilation technique that breathes with the patient is called Neurally Adjusted Ventilatory Assist, or NAVA, developed by Getinge, a global leader in intensive care technology for both infants and adults. Electrodes on the catheter sense contractions in the diaphragm, resulting in an almost instantaneous signal that the patient wants to breathe. Synchronously, the ventilator supplies air. And when the electrodes sense the end of diaphragmatic contractions, the ventilator allows exhalation. Adults on ventilators generally start with a functioning diaphragm, but it will quickly become weaker if a machine breathes for them for too long. Getinge Medical Director Miray Kärnekull says that advanced ventilator technologies like NAVA are used regularly in adult patients in Europe to keep patients' diaphragm muscles active. And in a very recent multicenter randomised controlled trial, results showed that patients with acute respiratory failure on NAVA spent significantly less time on the ventilator and experienced less extubation failure compared to conventional lung-protective mechanical ventilation. Annuncio • Oct 02
Getinge AB to Report Q3, 2020 Results on Oct 16, 2020 Getinge AB announced that they will report Q3, 2020 results at 8:00 AM, Central European Standard Time on Oct 16, 2020 Annuncio • Sep 24
Getinge Announces Voluntary Recall of the Servo-i Ventilator System's Nebulizer Connector Getinge is announcing a voluntary medical device recall for the Servo-i ventilator system due to a potentially shorter than specified nebulizer connector. This issue does not affect the functionality of the Servo-i ventilator system. To date, there have been no adverse events reported resulting in serious illness or injuries related to the mentioned component. Getinge has reported to relevant authorities according to applicable regulations and the cost for the recall is not material. Getinge has identified that 997 units have been manufactured that potentially could be affected by a shorter than specified nebulizer connector. This may result in difficulties in installing the Aeroneb® Nebulizer module to the Servo-i device. The module is an option on the Servo-i which is intended for administering drugs to patients requiring mechanical ventilation. This issue does not affect the functionality of the Servo-i ventilator system. The Servo-i ventilator is intended for ventilator support and can be used for Neonatal, Pediatric and Adult patients. Annuncio • Sep 17
Getinge AB Appoints Anna Romberg as Executive Vice President Legal, Compliance & Governance and Member, with Effect from October 01, 2020 Getinge AB appointed Anna Romberg as Executive Vice President Legal, Compliance & Governance and member of the Getinge Executive Team. She takes up the position on October 1st, 2020. Anna most recently worked as management consultant, supporting global companies with compliance matters. Prior to this, she held the position as Vice President Ethics and Compliance, Cargotec Oyj 2016 - 2019. She has also held several governance and compliance related roles at Telia Company AB. Anna is currently a PhD candidate within Corporate Governance and Compliance Management Systems at Åbo Akademi University and expects to finalize her degree during the year. She is also one of the founders of the Nordic Business Ethics Network. In her new role, Anna will be a member of the Getinge Executive Team and report to Mattias Perjos, President & CEO. She takes up the position on October 1st, 2020. 
